Sorrento receives authorisation from MHRA to conduct phase II trial of intranasal COVI-AMG neutralizing antibody (COVI-DROPS) in outpatient setting

Trial will recruit newly diagnosed SARS-CoV-2 infected patients. The neutralising antibody in the intranasal drops is claimed to be active against the original SARS-CoV-2 virus, as well as the UK/Alpha and India/Delta variants, currently prevalent in the UK and US.

Biospace Inc.